Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Investing in Drug Delivery Technologies: Fighting Patent Expiries

Abstract:
Combating losses due to patent expiries has become a high priority for pharmaceutical companies.

Investing in Drug Delivery Technologies: Fighting Patent Expiries

London, UK | Posted on September 18th, 2008



Investing in new drug delivery technologies is becoming a critical strategy for them to maintain a strong presence in this cut-throat market as they offer the potential to enhance the life cycle of established drugs.

A number of drug delivery, pharmaceutical and biotechnology companies are allocating significant resources towards the development of novel drug delivery systems. Once a small market, the drug delivery market is now poised for significant growth and holds great opportunities for both current players and new entrants.

"The global drug delivery market has witnessed encouraging growth in the past and is forecasted to gain significant importance in the coming years," notes Frost & Sullivan (healthcare.frost.com) Industry Analyst Sylvia Miriyam Findlay. "Heightened competition, the need to maximise revenues and combating patent expiries have forced pharmaceutical companies roll up their sleeves and seek out novel drug delivery systems."

Though the drug delivery market is dominated by oral forms of drugs (52 per cent of the market), other methods, particularly the non-invasive forms - pulmonary, transdermal and nanotechnology - are growing at a rapid pace.

The systemic delivery of drugs through pulmonary means has been the subject of significant research in the medical community. No longer confined to the treatment of respiratory diseases, the successes of dry powder inhalation have pushed the inhalation market to a new level.

Trasndermal drug delivery has also been gaining momentum as certain applications, such as contraceptive patches, have been found to be as effective as their oral counterparts. Cancer pain medication - Fentanyl - has been delivered transdermally and has witnessed increased uptake because of its convenience. Neurological and diabetes medications are other therapeutic drugs that are being investigated for transdermal drug delivery.

One of the most promising areas in drug delivery is nanotechnology. Nano-enabled drug delivery offers tremendous advantages over the current forms of drug delivery such as enhanced solubility, commendable bio-availability, better targeting and controlled delivery.

"The Nanotechnology-based drug delivery market is expected to garner $700-$800 billion revenues by 2015," says Findlay. "The market will be driven by the expanding horizon of therapeutic applications. Venture capital investments in nanotechnology drug delivery companies have been increasing and have therefore provided a positive spin to the market growth."

For many pharmaceutical and biotechnology companies, forging alliances with pure-play drug delivery companies offer the best opportunities to gain access to novel technologies. This can become a crucial strategy for pharmaceutical players to hold onto their market presence.

"Frost & Sullivan's analysis reveals that pharmaceutical companies look for various parameters before forging alliances with drug delivery companies," Findlay says. "A technological edge is most critical, as novel drug delivery methods should focus on providing the maximum patient benefits in addition to having commercial viability."

Frost & Sullivan believes that continuous research efforts in the area of drug delivery will enable the production of novel drug/device combinations. In addition, the future is bound to witness advancements in protein delivery through oral, nasal, buccal, pulmonary and transdermal delivery systems.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European drug delivery market-opportunity analysis, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

####

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

For more information, please click here

Contacts:
Patrick Cairns
+27 18 468 2315 patrick.cairns[.]frost.com

Copyright © Newswire Today

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Canatu Launches CNB In-Mold Film for Transparent Touch on 3D Surfaces –in Cars, Household Appliances, Wearables, Portables November 20th, 2014

Sustainable Nanotechnologies Project November 20th, 2014

Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014

UO-industry collaboration points to improved nanomaterials: University of Oregon microscope puts spotlight on the surface structure of quantum dots for designing new solar devices November 20th, 2014

Nanomedicine

Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Tokyo Institute of Technology research: Protein-engineered cages aid studies of cell functions November 19th, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Announcements

Purdue 3-D printing innovation capable of making stronger, lighter metal works for auto, aerospace industries November 20th, 2014

Leica Microsystems Presents Universal Hybrid Detector for Single Molecule Detection and Imaging at SfN and ASCB: Leica HyD SMD - the Optimal Detector for Precise and Reliable SMD data November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Nano Sorbents Able to Remove Pollutions Caused by Oil Derivatives November 20th, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Quantum mechanical calculations reveal the hidden states of enzyme active sites November 20th, 2014

UO-industry collaboration points to improved nanomaterials: University of Oregon microscope puts spotlight on the surface structure of quantum dots for designing new solar devices November 20th, 2014

Silver Nanoparticles Produced in Iran from Forest Plants Extract November 20th, 2014

Nano Sorbents Able to Remove Pollutions Caused by Oil Derivatives November 20th, 2014

Patents/IP/Tech Transfer/Licensing

Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014

First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014

Ki-Bum Lee Patents Technology To Advance Stem Cell Therapeutics November 13th, 2014

'Direct writing' of diamond patterns from graphite a potential technological leap November 5th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE